Investment in Joint Ventures (Details Textual) (USD $) Share data in Millions, except Per Share data, unless otherwise specified	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended		9 Months Ended	3 Months Ended			9 Months Ended			3 Months Ended	9 Months Ended			3 Months Ended	9 Months Ended		3 Months Ended	9 Months Ended
	May 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Mar. 31, 2013	Sep. 30, 2014 Parent Company	Sep. 30, 2014 Medical Joint Venture	Dec. 31, 2013 Medical Joint Venture	Sep. 30, 2013 Medical Joint Venture	Sep. 30, 2014 Medical Joint Venture Instruments	Sep. 30, 2013 Medical Joint Venture	Mar. 31, 2011 Medical Joint Venture	Sep. 30, 2014 Education Joint Venture	Sep. 30, 2014 Education Joint Venture	Dec. 31, 2013 Education Joint Venture	Mar. 31, 2013 Education Joint Venture	Sep. 30, 2014 Milestone China	Sep. 30, 2014 Milestone China	Jun. 30, 2014 Milestone China	Sep. 30, 2014 Milestone China Net income	Sep. 30, 2014 Milestone China Net income
Investment in Medical Joint Venture (Textual) [Abstract]
Joint venture owned by the entity							50.00%							50.00%				50.00%			40.00%
Contribution of Milestone in joint venture								$ 245,000				$ 1,500,000
Capital contribution									1,500,000			1,500,000
Instrument inception period												30 months
Contingency associated with the return of capital to Beijing 3H									0			0
Number of development of instruments												2
Sale of stock, number of shares										2
Sale of stock, price per share										$ 1.50
Sale of stock, value										3,000,000
Net proceeds received in joint venture	10,000,000									2,363,000
Percentage of ownership before transaction										50.00%
Percentage of ownership after transaction										45.50%
Gain on dilutive effect										1,363,650
Loss on joint venture		(223,834)	(212,199)	(567,550)	(259,291)
Legal fees related to the FDA (510k) certifications		44,415		175,868
Investment in Milestone Medical Inc		619,574		619,574		924,115
Net loss		(358,490)	218,523	(333,113)	443,277	1,464,930			(492,441)			(1,248,625)
Reimbursable expense included in account receivable, net									117,551			117,551
Other charges		196,284	217,749	547,661	311,868				168,500		132,787	300,930	141,834
Loan from parent company CEO							50,000
Income (loss) on joint venture															(2,663)	(10,455)			29,428	29,428		73,570	73,570
Percentage of gain/loss on joint venture															50.00%	50.00%			40.00%	40.00%
Investment															31,627	31,627	42,082		165,229	165,229	1,000,000
Distributor price per instrument																					$ 1,295
Net Investment Income															$ (2,663)	$ (10,455)			$ 29,428	$ 29,428		$ 73,570	$ 73,570